US equities |
SPCX $166.63 ▲+4.83% NVDA $236.89 ▲+1.26% MU $1,064.89 ▼-0.93% TSLA $377.36 ▲+1.83% MSFT $526.21 ▲+1.68% SNDK $1,713.06 ▼-0.40% INTC $117.32 ▼-1.68% META $745.29 ▲+2.36%
FinancialContent

Cue Biopharma, Inc. - Common Stock (NQ:CUE)

22.89 -2.68 (-10.48%)
Delayed Quote Updated: 11:50 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cue Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 21, 2023 ↗
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million. 
Via Benzinga
News headline image
Cue Biopharma's Earnings Outlook ↗
 
Via Benzinga
News headline image
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at Two February 2023 Scientific Conferences
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Announces Chief Medical Officer Transition
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)
Via ACCESSWIRE
News headline image
Cue Biopharma Reports Third Quarter 2022 Financial Results
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Good morning, traders! We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning! 
Via InvestorPlace
News headline image
Why Soluna Holdings Shares Are Trading Sharply Lower; Here Are 38 Stocks Moving Premarket ↗
Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) rose 70.8% to $0.41 in pre-market trading. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. 
Via Benzinga
News headline image
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday. 
Via Benzinga
News headline image
Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-off ↗
Cue Biopharma (NASDAQ: CUE) has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102 for the treatment of patients with Wilms' Tumor 1 (WT1)-positive recurrent/metastatic... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
On Tuesday, 87 companies hit new 52-week lows. 
Via Benzinga
News headline image
Cue Biopharma's Return On Capital Employed Overview ↗
Benzinga Pro data, Cue Biopharma (NASDAQ:CUE) reported Q1 sales of $1.00 million. Earnings fell to a loss of $14.26 million, resulting in a 70.02% decrease from last quarter. 
Via Benzinga
News headline image
FDA Accepts IND for Cue Biopharma's CUE-102 in the treatment of Wilms' Tumor 1 (WT1) ↗
Cue Biopharma, Inc. (NASDAQ: CUE) received the U.S. Food and Drug Administration (FDA) acceptance of the Investigational New Drug (IND) application for the evaluation of CUE-102 in the treatment of... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >